======= BEND3 =======
== Gene Information ==
* **Official Symbol**: BEND3
* **Official Name**: BEN domain containing 3
* **Aliases and Previous Symbols**: N/A
* **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=57673|57673]]
* **UniProt**: [[https://www.uniprot.org/uniprot/Q5T5X7|Q5T5X7]]
* **Interactions**: [[https://thebiogrid.org/search.php?search=BEND3&organism=9606|BioGRID]]
* **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20BEND3|Open PubMed]]
* **OMIM**: [[https://omim.org/entry/616374|Open OMIM]]
== Function Summary ==
* **Entrez Summary**: N/A
* **UniProt Summary**: Transcriptional repressor which associates with the NoRC (nucleolar remodeling complex) complex and plays a key role in repressing rDNA transcription. The sumoylated form modulates the stability of the NoRC complex component BAZ2A/TIP5 by controlling its USP21-mediated deubiquitination (PubMed:21914818, PubMed:26100909). Binds to unmethylated major satellite DNA and is involved in the recruitment of the Polycomb repressive complex 2 (PRC2) to major satellites (By similarity). Stimulates the ERCC6L translocase and ATPase activities (PubMed:28977671). {ECO:0000250|UniProtKB:Q6PAL0, ECO:0000269|PubMed:21914818, ECO:0000269|PubMed:26100909, ECO:0000269|PubMed:28977671}.
|BEN|
|histone H3-K9 trimethylation|
|rDNA binding|
|histone H4-K20 trimethylation|
|histone H3-K27 trimethylation|
|histone H4-K20 methylation|
|histone H3-K27 methylation|
|chromatin silencing at rDNA|
|histone H3-K9 methylation|
|histone H3-K4 trimethylation|
|histone H3-K9 modification|
|nuclear heterochromatin|
|peptidyl-lysine trimethylation|
|histone H3-K4 methylation|
|positive regulation of ATP metabolic process|
|DNA alkylation|
|DNA methylation|
|histone H4 acetylation|
|chromatin organization involved in negative regulation of transcription|
|chromatin silencing|
|DNA methylation or demethylation|
|chromatin organization involved in regulation of transcription|
|histone lysine methylation|
|negative regulation of gene expression, epigenetic|
|peptidyl-lysine methylation|
|DNA modification|
|histone methylation|
|histone acetylation|
|internal peptidyl-lysine acetylation|
|regulation of ATP metabolic process|
|peptidyl-lysine acetylation|
|internal protein amino acid acetylation|
|protein alkylation|
|protein methylation|
|protein acetylation|
|gene silencing|
|protein acylation|
|regulation of gene expression, epigenetic|
|macromolecule methylation|
|methylation|
|peptidyl-lysine modification|
|protein homooligomerization|
|histone modification|
|covalent chromatin modification|
|protein complex oligomerization|
|chromatin organization|
|DNA metabolic process|
|nucleolus|
|negative regulation of transcription by RNA polymerase II|
|peptidyl-amino acid modification|
|chromosome organization|
|negative regulation of transcription, DNA-templated|
|negative regulation of nucleic acid-templated transcription|
|negative regulation of RNA biosynthetic process|
|negative regulation of RNA metabolic process|
|negative regulation of cellular macromolecule biosynthetic process|
|negative regulation of nucleobase-containing compound metabolic process|
|negative regulation of macromolecule biosynthetic process|
|negative regulation of cellular biosynthetic process|
|negative regulation of biosynthetic process|
|protein-containing complex assembly|
|negative regulation of gene expression|
|protein-containing complex subunit organization|
\\
=== CRISPR Data ===
^Screen^Score^
|[[:results:exp527|Tanespimycin 14μM R08 exp527]]|1.77|
|[[:results:exp355|Dinaciclib 0.007μM R07 exp355]]|1.78|
|[[:results:exp106|UM131593 0.2μM R03 exp106]]|1.86|
|[[:results:exp533|TNF-alpha 44ng/ml R08 exp533]]|2.02|
|[[:results:exp534|Trientine 500μM R08 exp534]]|2.21|
|[[:results:exp365|I-BRD9 4μM R07 exp365]]|2.23|
|[[:results:exp36|TRAIL 50ng/ml R00 exp36]]|2.34|
|[[:results:exp282|Fluvastatin 2.2μM R06 exp282]]|2.36|
|[[:results:exp28|Pimelic-diphenylamide-106 5μM R00 exp28]]|2.64|
|[[:results:exp35|TRAIL 5ng/ml R00 exp35]]|2.76|
|[[:results:exp447|Amiloride 100μM R08 exp447]]|3|
|[[:results:exp409|THZ531 0.11μM R07 exp409]]|3.47|
|[[:results:exp410|THZ531 0.11 to 0.125μM on day4 R07 exp410]]|4.14|
|[[:results:exp102|Nifuroxazide 5μM R03 exp102]]|4.31|
|[[:results:exp413|THZ531 0.11 to 0.175μM on day4 R07 exp413]]|6.37|
|[[:results:exp505|ML-792 0.2μM R08 exp505]]|6.42|
|[[:results:exp531|THZ1 0.06μM R08 exp531]]|7.22|
|[[:results:exp412|THZ531 0.11 to 0.125 to 0.35μM on day4 then day6 R07 exp412]]|7.43|
|[[:results:exp444|THZ531 0.225μM R08 exp444]]|8.1|
|[[:results:exp21|MLN-4924 0.2μM R00 exp21]]|8.48|
No correlation found to any other genes in chemogenomics.
Global Fraction of Cell Lines Where Essential: 1/739
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|0/1|
|909776.0|0/1|
|bile duct|0/28|
|blood|0/28|
|bone|0/26|
|breast|0/33|
|central nervous system|0/56|
|cervix|0/4|
|colorectal|0/17|
|esophagus|0/13|
|fibroblast|0/1|
|gastric|0/16|
|kidney|1/21|
|liver|0/20|
|lung|0/75|
|lymphocyte|0/16|
|ovary|0/26|
|pancreas|0/24|
|peripheral nervous system|0/16|
|plasma cell|0/15|
|prostate|0/1|
|skin|0/24|
|soft tissue|0/9|
|thyroid|0/2|
|upper aerodigestive|0/22|
|urinary tract|0/29|
|uterus|0/5|
== Essentiality in NALM6 ==
* **Essentiality Rank**: 3042
* **Expression level (log2 read counts)**: 5.46
{{:chemogenomics:nalm6 dist.png?nolink |}}